Hematopoietic Cell Patents (Class 424/173.1)
-
Publication number: 20150132255Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.Type: ApplicationFiled: June 6, 2013Publication date: May 14, 2015Applicant: Bionor Immuno ASInventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
-
Patent number: 9028826Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.Type: GrantFiled: March 13, 2013Date of Patent: May 12, 2015Assignee: The Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Publication number: 20150125470Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: March 29, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Jun Hasegawa
-
Publication number: 20150125447Abstract: The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.Type: ApplicationFiled: November 5, 2014Publication date: May 7, 2015Inventor: Karl-Heinz HEIDER
-
Publication number: 20150118252Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.Type: ApplicationFiled: June 13, 2013Publication date: April 30, 2015Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
-
Patent number: 9017682Abstract: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.Type: GrantFiled: September 14, 2012Date of Patent: April 28, 2015Assignee: Val-Chum, Limited PartnershipInventors: Alexandre Prat, Romain Cayrol, Nathalie Arbour
-
Publication number: 20150110813Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.Type: ApplicationFiled: November 13, 2014Publication date: April 23, 2015Inventors: Hong Jiang, Leonard Chess
-
Publication number: 20150104467Abstract: Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking A?-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking A?-induced integrin activation, degranulation and/or ROS release in neutrophil/myeloid cells.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventor: Gabriela Constantin
-
Publication number: 20150098942Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.Type: ApplicationFiled: February 6, 2012Publication date: April 9, 2015Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical CenterInventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
-
Publication number: 20150098939Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.Type: ApplicationFiled: August 29, 2014Publication date: April 9, 2015Applicant: SANOFIInventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
-
Publication number: 20150086548Abstract: Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks or destroys the autoimmune destruction of pancreatic cells or agents that optimize function within existing islets in patients with type 1 diabetes, type 2 diabetes and related conditions.Type: ApplicationFiled: September 5, 2014Publication date: March 26, 2015Inventor: Claresa S. Levetan
-
Publication number: 20150086616Abstract: Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer's disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat Alzheimer's disease, a low grade brain inflammation. The large amount of nasal NSAIDs (e.g., ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen) that reaches the brain far exceeds that from an oral dose. Low-molecular-weight lipophilic drugs, such as ibuprofen, naproxen, indomethacin, diclofenac, and flurbiprofen, are readily absorbed into the brain by the intranasal route. Alzheimer's starts in the entorhinal cortex, which is closely connected to the olfactory nerves, and spreads anatomically in a defined pattern. Therefore, a nasal NSAID would readily reach the region of the brain where it acts therapeutically.Type: ApplicationFiled: September 18, 2014Publication date: March 26, 2015Inventor: Steven Lehrer
-
Publication number: 20150086574Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.Type: ApplicationFiled: August 12, 2014Publication date: March 26, 2015Inventors: Holger Karsunky, Ying-Ping Jiang
-
Publication number: 20150064196Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.Type: ApplicationFiled: October 8, 2014Publication date: March 5, 2015Inventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
-
Publication number: 20150056186Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.Type: ApplicationFiled: March 27, 2014Publication date: February 26, 2015Applicant: Hoffmann-La Roche Inc.Inventors: THOMAS FRIESS, CHRISTIAN KLEIN, PAMELA STREIN, PABLO UMANA
-
Publication number: 20150056167Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: September 4, 2014Publication date: February 26, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Patent number: 8962806Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: December 29, 2008Date of Patent: February 24, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's HospitalInventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
-
Patent number: 8961976Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: December 19, 2013Date of Patent: February 24, 2015Assignee: Biogen Idec Ma Inc.Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf
-
Patent number: 8956615Abstract: T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.Type: GrantFiled: September 13, 2013Date of Patent: February 17, 2015Assignee: La Jolla Institute for Allergy and ImmunologyInventors: Michael Croft, Shahram Salek-Ardakani
-
Publication number: 20150044164Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: November 19, 2012Publication date: February 12, 2015Applicant: GENZYME CORPORATIONInventors: Johanne KAPLAN, John M. McPHERSON
-
Publication number: 20150044230Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: ApplicationFiled: August 20, 2014Publication date: February 12, 2015Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Publication number: 20150044231Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: ApplicationFiled: August 25, 2014Publication date: February 12, 2015Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
-
Patent number: 8951518Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: GrantFiled: July 13, 2012Date of Patent: February 10, 2015Assignees: Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Publication number: 20150037278Abstract: The invention relates to a method for predicting an improved therapeutic benefit for an individual with a tumor load before initiating an immune therapy which is capable of activating immune cells against said tumor as well as to pharmaceutical compositions for use in this method.Type: ApplicationFiled: May 16, 2012Publication date: February 5, 2015Applicants: Michael Stroehlein, Markus HeissInventors: Horst Lindhofer, Markus Heis, Michael Stroehlein
-
Patent number: 8945565Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: GrantFiled: December 21, 2010Date of Patent: February 3, 2015Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research FoundationInventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Patent number: 8945564Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.Type: GrantFiled: April 17, 2007Date of Patent: February 3, 2015Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
-
Publication number: 20150017185Abstract: The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and/or preventing an immune condition in a subject, which comprises the step of enhancing the immune function of a memory T cell in the subject by such a method. There is also provided a pharmaceutical composition or kit comprising an agent capable of inhibiting signalling via an inhibitory receptor which regulates T cell exhaustion, such as PD-1, and an agent capable of inhibiting the p38 MAP kinase signalling pathway.Type: ApplicationFiled: November 29, 2012Publication date: January 15, 2015Inventors: Arne Akbar, Sian Henson
-
Publication number: 20150017121Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.Type: ApplicationFiled: October 10, 2012Publication date: January 15, 2015Applicant: UNIVERSITAT ZURICHInventors: Burkhard Becher, Johannes Vom Berg
-
Publication number: 20150010508Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.Type: ApplicationFiled: July 21, 2014Publication date: January 8, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION
Publication number: 20150010581Abstract: The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (AAT) and temporary T-cell depletion including but not limited to anti-CD4 and anti-CD8 antibodies.Type: ApplicationFiled: February 27, 2013Publication date: January 8, 2015Inventor: Eli Lewis -
Publication number: 20150010496Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.Type: ApplicationFiled: November 30, 2012Publication date: January 8, 2015Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
-
Patent number: 8926979Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: GrantFiled: November 1, 2006Date of Patent: January 6, 2015Assignees: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20150004163Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.Type: ApplicationFiled: July 7, 2014Publication date: January 1, 2015Inventors: Cory AHONEN, Randolph NOELLE
-
Publication number: 20140377283Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.Type: ApplicationFiled: September 5, 2014Publication date: December 25, 2014Inventors: Bjorn SKOGEN, Anne HUSEBEKK, Mette Kjaer KILLIE, Jens KJELDSEN-KRAGH
-
Publication number: 20140377181Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: June 20, 2014Publication date: December 25, 2014Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLCInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Publication number: 20140377257Abstract: The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist.Type: ApplicationFiled: May 30, 2014Publication date: December 25, 2014Applicant: GENENTECH, INC.Inventors: Andrew CHAN, Qian GONG, Flavius MARTIN
-
Publication number: 20140370033Abstract: The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventor: Timothy Ruben Dirk Jan Radstake
-
Publication number: 20140370007Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Applicant: Advanced Cell Technology, Inc.Inventors: Kathryn L. McCabe, Shi-Jiang Lu, Robert P. Lanza
-
Patent number: 8911726Abstract: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.Type: GrantFiled: September 22, 2005Date of Patent: December 16, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Nobuaki Takahashi, Hideaki Yoshida
-
Patent number: 8911739Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.Type: GrantFiled: February 9, 2010Date of Patent: December 16, 2014Assignees: Trustees of Columbia University in the City of New York, The National Institutes of Health (NIH)Inventors: Hong Jiang, Leonard Chess
-
Publication number: 20140348786Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: August 7, 2014Publication date: November 27, 2014Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Patent number: 8895010Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: October 12, 2012Date of Patent: November 25, 2014Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Publication number: 20140341971Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: ApplicationFiled: June 20, 2014Publication date: November 20, 2014Applicants: LIPOTEK PTY LTD, DOMANTIS LIMITEDInventors: Joseph ALTIN, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Patent number: 8889362Abstract: The present invention involves the reaction of a CD4 immuno-conjugate with a sample of patient whole blood. The CD4 immuno-conjugate consists of one or more antibodies with specificity for the CD4 surface receptor coupled to a signal moiety, or “label”, that is detectable by a flow cytometer. Such labels may generate a signal by such means as fluorescence properties, light scatter properties, electronic properties, or magnetic properties. The CD4 immuno-conjugate binds to both the CD4 positive lymphocytes (Helper T cells) and all monocytes. Differential detection means are employed to count immuno-conjugate labeled Helper T cells. The present invention distinguishes itself by simultaneously measuring the signal level from monocytes as a means to verify sufficient activity of the anti-CD4 antibody.Type: GrantFiled: January 30, 2007Date of Patent: November 18, 2014Assignee: Point Care TechnologiesInventor: Peter W. Hansen
-
Publication number: 20140335105Abstract: A method of generating a hyper iNOS expressing cell includes administering to a myeloid derived cell an amount of a PPAR? agonist and an IL-6/STAT3 signaling pathway antagonist effective to substantially inhibit STAT3 activation in the cell and administering an inflammatory insult to the cell to stimulate hyper iNOS expression from the cell.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: KURT Q. LU, KEVIN D. COOPER, BRYAN W. DOREIAN
-
Publication number: 20140328843Abstract: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies bind Fc?RIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-Fc?RIIB antibody and an anti-CD20 antibody.Type: ApplicationFiled: June 4, 2014Publication date: November 6, 2014Applicant: MACROGENICS, INC.Inventors: Nadine Tuaillon, Christopher Rankin
-
Publication number: 20140314753Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a 5-Substituted Quinazolinone Compound to a patient having a cancer.Type: ApplicationFiled: April 16, 2014Publication date: October 23, 2014Applicant: Signal Pharmaceuticals, LLC.Inventors: KRISTEN MAE HEGE, RAJESH CHOPRA
-
Patent number: 8852597Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.Type: GrantFiled: April 4, 2012Date of Patent: October 7, 2014Assignee: The Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Patent number: 8852551Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: December 11, 2009Date of Patent: October 7, 2014Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20140294824Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: March 21, 2014Publication date: October 2, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou